Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsCLVLF -0.51%85 Cash-to-Debt is 130.05 as of Jun. 2026, which is 9% below its 10-year median of 143.40. GuruFocus rates CLVLF with a GF Score™ of 85/100 and a GF Value™ of $9.34 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,397 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 78.45% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Clinuvel Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2026 was 130.05.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Clinuvel Pharmaceuticalscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Clinuvel Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
CLVLF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 50.6 Med: 143.4 Max: No Debt
Current: 129.99
During the past 13 years, Clinuvel Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 50.60. And the median was 143.40.
CLVLF's Cash-to-Debt is ranked better than 78.45% of 1397
companies
in the Biotechnology industry
Industry Median: 6.78
vs CLVLF: 129.99
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Clinuvel Pharmaceuticals Cash-to-Debt Related Terms
Clinuvel Pharmaceuticals Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CLVLF vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (CLVLF) has a Cash-to-Debt of 130.05 as of Jun. 2026. This is near median its historical median of 143.40. Over the past decade, Clinuvel Pharmaceuticals' Cash-to-Debt has ranged from 50.60 to 10,000.00. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #301 out of 1397 companies in the Biotechnology industry, placing it in the top 21.5%.
Is Clinuvel Pharmaceuticals' Cash-to-Debt too high?
Clinuvel Pharmaceuticals' current Cash-to-Debt of 130.05 is near median its 10-year median of 143.40. Over the past 10 years, this metric has ranged from a low of 50.60 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.78. Clinuvel Pharmaceuticals' value of 130.05 is 1818.1% above this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #301 out of 1397 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #301 out of 1397 companies for Cash-to-Debt. This places Clinuvel Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.78. Clinuvel Pharmaceuticals' value of 130.05 is 1818.1% above this benchmark. Historically, Clinuvel Pharmaceuticals' own Cash-to-Debt has ranged from 50.60 to 10,000.00 over the past decade. While the company's 10-year median is 143.40 vs. the industry median of 6.78, Clinuvel Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current Cash-to-Debt of 130.05 is 1818.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current Cash-to-Debt is 130.05, which is near median its own 10-year median of 143.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLF) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.34, compared to a current price of $5.89 — trading 36.9% below its estimated fair value. The current Cash-to-Debt is 130.05, which is near median its 10-year median of 143.40 and 1818.1% above the Biotechnology industry median of 6.78. Clinuvel Pharmaceuticals' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLF), the current Cash-to-Debt is 130.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (CLVLF) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of $5.89 is trading 36.9% below its estimated GF Value™ of $9.34.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for CLVLF:
Cash-to-Debt: 130.05 (near median its 10-year median of 143.40)
GF Value™: $9.34 vs. price of $5.89 (36.9% below fair value)
Industry Position: 1818.1% above the Biotechnology median (#301 of 1397)
No single metric tells the full story. See the CLVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
85GF Score
Get the complete analysis for CLVLF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVLF has been successfully added to your 
